Takeda reported that zasocitinib, the TYK2 inhibitor it acquired in a $4 billion deal, met co‑primary and top secondary endpoints in two Phase 3 psoriasis trials. The company said the oral therapy showed superiority versus placebo and Amgen’s Otezla after four months on key severity measures. Takeda plans to present full data at a medical meeting and to seek regulatory approvals in the U.S. and elsewhere in fiscal 2026. The trials’ success validates the selectivity argument that underpinned the high‑value acquisition from Nimbus Therapeutics and positions zasocitinib as a potential oral alternative to injectable biologics. Takeda is also testing the molecule in additional inflammatory indications and a head‑to‑head versus Bristol Myers Squibb’s Sotyktu, intensifying competition in the oral autoimmune space. Investors and competitors will watch safety signals and longer‑term readouts closely; the company reported common adverse events including respiratory infections, colds and acne, and will provide detailed safety and efficacy data at upcoming scientific forums.